Literature DB >> 34214192

Essential requirement for polypyrimidine tract binding proteins 1 and 3 in the maturation and maintenance of mature B cells in mice.

Elisa Monzón-Casanova1,2, Kirsty J Bates1, Christopher W J Smith2, Martin Turner1.   

Abstract

The maturation of immature B cells and the survival of mature B cells is stringently controlled to maintain a diverse repertoire of antibody specificities while avoiding self-reactivity. At the molecular level this is regulated by signaling from membrane Ig and the BAFF-receptor that sustain a pro-survival program of gene expression. Whether and how posttranscriptional mechanisms contribute to B cell maturation and survival remains poorly understood. Here, we show that the polypyrimidine tract binding proteins (PTBP) PTBP1 and PTBP3 bind to a large and overlapping set of transcripts in B cells. Both PTBP1 and PTBP3 bind to introns and exons where they are predicted to regulate alternative splicing. Moreover, they also show high-density of binding to 3' untranslated regions suggesting they influence the transcriptome in diverse ways. We show that PTBP1 and PTBP3 are required in B cells beyond the immature cell stage to sustain transitional B cells and the B1, marginal zone and follicular B cell lineages. Therefore, PTBP1 and PTBP3 promote the maturation of quiescent B cells by regulating gene expression at the posttranscriptional level.
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.

Entities:  

Keywords:  PTBP1; PTBP3; RNA binding proteins; mature B cells; posttranscriptional gene expression regulation

Mesh:

Substances:

Year:  2021        PMID: 34214192     DOI: 10.1002/eji.202149257

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Polypyrimidine tract binding protein 1 regulates the activation of mouse CD8 T cells.

Authors:  Vanessa D'Angeli; Elisa Monzón-Casanova; Louise S Matheson; Özge Gizlenci; Georg Petkau; Clare Gooding; Rebecca V Berrens; Christopher W J Smith; Martin Turner
Journal:  Eur J Immunol       Date:  2022-04-29       Impact factor: 6.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.